Inhibikase Therapeutics, Inc. announced that it will receive $7,999,999 in funding on May 20, 2024. The company will issue common shares in the transaction. The company will issue securities pursuant to exemption provided under Regulation D.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1.315 USD | -5.09% |
|
-8.39% | +3.15% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+3.15% | 10M | |
+23.97% | 52.73B | |
+37.49% | 39B | |
-9.35% | 38.52B | |
+29.57% | 30.38B | |
-12.26% | 26.39B | |
+11.39% | 26.08B | |
+45.03% | 14.15B | |
+32.51% | 12.6B | |
-5.72% | 11.51B |
- Stock Market
- Equities
- IKT Stock
- News Inhibikase Therapeutics, Inc.
- Inhibikase Therapeutics, Inc. announced that it expects to receive $7.999999 million in funding